Table 1 Baseline demographic and clinical characteristics
From: Myocardial protection with phosphocreatine in high-risk cardiac surgery patients: a randomized trial
Placebo (n = 63) | Phosphocreatine (n = 57) | |
|---|---|---|
Age (y) | 57 (46–65) | 58 (51–64) |
LVEF (%) | 64 (58–70) | 63 (57–66) |
EUROSCORE II | 1.88 (1.28–2.99) | 2.2 (1.6–2.99) |
Males % | 29 (46%) | 18 (31%) |
Redo cardiac surgery | 8 (13%) | 6 (11%) |
Previous MI | 1 (1.6%) | 0 |
Hypertension | 21 (33%) | 22 (39%) |
Atrial fibrillation | 20 (32%) | 27 (47%) |
COPD | 5 (7.9%) | 3 (5.3%) |
Carotid stenosis | 4 (6.3%) | 4 (7.0%) |
Previous stroke/TIA | 6 (9.5%) | 2 (2.5%) |
Diabetes mellitus | 5 (7.9%) | 5 (8.8%) |
Active smokers | 4 (6.4%) | 4 (7.0%) |
Cardiac catheterization < 48 h of surgery | 16 (26%) | 11 (19%) |
Medications | ||
Diuretics | 30 (48%) | 36 (63%) |
Beta-blockers | 22 (36%) | 28 (49%) |
ACE inhibitors | 14 (23%) | 16 (28) |
Anticoagulants | 15 (24%) | 15 (26%) |
Statins | 9 (15%) | 5 (8.8%) |
Digoxin | 5 (7.9%) | 7 (12%) |
Platelet inhibitors | 4 (6.4%) | 4 (7.0%) |
ARBs | 4 (6.4%) | 7 (12%) |
Calcium channel blockers | 4 (6.4%) | 3 (5.3%) |
Ivabradine | 1 (1.6%) | 1 (1.7%) |
NYHA class | ||
I | 4 (6.4%) | 1 (1.8%) |
II | 23 (85%) | 20 (95%) |
III | 35 (56%) | 34 (61%) |
IV | 1 (1.6%) | 1 (1.8%) |